WebDoctor Encyclopedia

Ovarian

Clear cell ovarian carcinoma

Clear cell ovarian carcinoma is an epithelial ovarian cancer closely linked with endometriosis. It is often found early, but advanced disease responds poorly to standard chemotherapy.

Medically reviewed Last reviewed October 17, 2026

What is clear cell ovarian carcinoma?

Clear cell ovarian carcinoma is a distinct type of epithelial ovarian cancer. It is named after the pale, “clear” look of its cells under the microscope, which comes from stored sugar (glycogen).

It makes up about 5-10% of ovarian cancers in Europe and North America, but up to 20-25% in Japan and other parts of East Asia.

Clear cell carcinoma is closely linked with endometriosis, a common condition in which tissue similar to the womb lining grows outside the womb. Many tumours develop in an endometriosis cyst of the ovary (an endometrioma, or “chocolate cyst”).

Compared with the commonest ovarian cancer, high-grade serous carcinoma, it is more often found early, while it is still confined to the ovary. Early-stage disease has a good outlook after surgery.

When it has spread, however, clear cell carcinoma responds poorly to standard chemotherapy. It also carries a higher risk of blood clots. Research into new treatments, such as immunotherapy and drugs aimed at its gene changes, is active.

1. Key facts at a glance

Feature Details
Type of cancer Epithelial ovarian cancer, clear cell type
How common About 5-10% of ovarian carcinomas in Western countries; up to 20-25% in Japan
Typical age Median about 50-55; younger than for serous cancer
Main risk factor Endometriosis
Stage at diagnosis About half or more are stage I-II
Key gene changes ARID1A loss in about half; PIK3CA mutations in about 40-50%
Special features High risk of blood clots; occasionally high blood calcium
Main treatments Surgery with full staging; carboplatin and paclitaxel; trials of immunotherapy and targeted drugs
Outlook Stage I: about 85-90% alive at 5 years; stage III-IV: about 20-30%

2. How it differs from other ovarian cancers

Feature Clear cell High-grade serous Endometrioid
Link with endometriosis Strong Weak Strong
Usual stage at diagnosis Often early Usually advanced Often early
Response to platinum chemotherapy Poor in advanced disease Usually good at first Usually good
Key genes ARID1A, PIK3CA TP53, BRCA1/2 ARID1A, CTNNB1, PTEN
PARP inhibitors Little benefit Important treatment Selected cases
CA125 Often only mildly raised Usually very high Variable

3. Causes and risk factors

Factor Notes
Endometriosis Raises the risk of clear cell carcinoma about three-fold; still, very few women with endometriosis develop it
East Asian ancestry Higher rates in Japan and other parts of Asia
Lynch syndrome An inherited condition with faulty mismatch repair genes; linked to clear cell and endometrioid ovarian cancer
Never having children Associated with higher risk of ovarian cancer generally
Gene changes in the tumour ARID1A and PIK3CA changes, often already found in the nearby endometriosis
Protective factors Tubal ligation and hysterectomy are linked to a lower risk of endometriosis-related ovarian cancers

Endometriosis affects about 1 in 10 women of reproductive age, so the absolute risk of clear cell carcinoma remains small. Women with endometriosis do not need routine cancer screening, but endometriosis cysts that grow, develop solid areas or appear after the menopause should be checked with a specialist scan.

4. How does it look?

4.1 Inside the body and at surgery

Feature What it looks like
Size Often a large mass, commonly 10-15 cm
Side Usually one ovary
Inside A cyst with one or more solid, fleshy nodules growing from the wall
Fluid Often dark brown “chocolate” fluid when it arises in an endometriosis cyst
Surrounding tissue Endometriosis on the pelvic lining, often with scarring and adhesions

4.2 On scans

Test Typical findings
Pelvic ultrasound A cyst with solid nodules that have a blood supply on Doppler
MRI A bright cyst on T1 images (from old blood) with enhancing solid nodules
CT Shows the extent of the tumour and spread, and can find blood clots

4.3 Under the microscope

Feature What the pathologist sees
Cells Clear or pink cells; “hobnail” cells with nuclei bulging into spaces
Patterns Tubules, cysts, papillae and solid sheets, often mixed
Stains Napsin A and HNF1-beta positive; usually oestrogen receptor and WT1 negative
Mismatch repair proteins Tested to look for Lynch syndrome
ARID1A Loss of the protein in about half of tumours

5. Symptoms

5.1 Common symptoms

Symptom Notes
Pelvic or lower tummy pain Often the first symptom
A lump or swelling in the tummy From a large ovarian mass
Bloating Persistent rather than coming and going
Feeling full quickly Pressure on the stomach
Changes in bladder or bowel habits Pressure from the mass
Symptoms of endometriosis Painful periods, pain during sex, long-standing pelvic pain

5.2 Warning signs of complications

Symptom Possible cause
Painful, swollen leg Deep vein thrombosis (blood clot)
Sudden breathlessness or chest pain Pulmonary embolism, an emergency
Thirst, confusion, constipation High blood calcium caused by the tumour
Sudden severe pain Twisting or rupture of the cyst

5.3 When to see a doctor

See a doctor if you have bloating, pelvic pain, a swollen tummy or early fullness on most days for three weeks or more. Women with known endometriosis should report a change in their usual symptoms or a cyst that grows. Get emergency help for sudden breathlessness or chest pain.

6. Diagnosis

Test Why it is done
Pelvic examination Feels for a mass
Transvaginal ultrasound The first imaging test; describes solid parts and blood flow
CA125 and other markers CA125 is often only mildly raised in clear cell carcinoma
MRI Helps tell an endometriosis cyst from a cancer
CT of chest, abdomen and pelvis Checks for spread and for blood clots
Surgery and pathology Usually provides the final diagnosis
Germline genetic testing Recommended for all women with epithelial ovarian cancer; includes Lynch syndrome genes

Staging

The FIGO staging system is used: stage I is confined to the ovaries, stage II spreads within the pelvis, stage III to the abdominal lining or lymph nodes, and stage IV to distant organs.

Conditions that can look similar

Condition How it differs
Endometrioma (“chocolate cyst”) A benign endometriosis cyst with dark fluid but no solid, enhancing nodules
Endometrioid ovarian carcinoma Also linked with endometriosis; different cells and usually ER positive
High-grade serous carcinoma with clear cells Has TP53 changes and WT1 staining
Yolk sac tumour A germ cell tumour of young women; raises AFP
Metastatic clear cell kidney cancer Spread from the kidney; usually CD10 and RCC marker positive, and kidney scans show the primary tumour

7. Treatment

Treatment is planned by a gynaecological oncology team at a specialist centre. Careful surgical staging is especially important, because finding the cancer at stage I can spare some women more intensive treatment.

7.1 Surgery

Procedure Notes
Hysterectomy and removal of both ovaries and tubes Standard surgery
Full staging Omentectomy, peritoneal biopsies and washings, and lymph node assessment for apparently early disease
Fertility-sparing surgery Only for carefully selected young women with stage IA disease, after specialist discussion
Debulking surgery For advanced disease, aiming to remove all visible tumour

7.2 Chemotherapy and other drugs

Chemotherapy for clear cell carcinoma uses the same drugs as for other ovarian cancers, mainly carboplatin and paclitaxel, usually given every three weeks for six cycles. Research has not yet found a regimen that works better for this type.

Situation Approach
Stage IA, fully staged Chemotherapy is discussed; some women may be safely observed
Stage IB-IC and II Carboplatin and paclitaxel is usually recommended
Stage III-IV Surgery plus carboplatin and paclitaxel, often with bevacizumab
Recurrence Other chemotherapy; immunotherapy or targeted drugs in trials; surgery for selected recurrences
Mismatch repair-deficient tumours Immune checkpoint drugs may work well

7.3 Prevention of blood clots

Blood clots in the legs or lungs affect a notable proportion of women with clear cell carcinoma, more than with other ovarian cancers. They can occur before diagnosis, around surgery or during chemotherapy.

Because the risk of clots is high, doctors give blood-thinning injections around surgery and sometimes during chemotherapy.

8. Side effects of treatment

Treatment Possible effects What helps
Surgery Pain, wound problems, blood clots, early menopause Pain relief, early walking, blood thinners, menopause advice
Carboplatin Low blood counts, tiredness, nausea Blood tests, anti-sickness medicines
Paclitaxel Hair loss, numbness in hands and feet, joint aches Cooling caps in some centres, dose changes
Bevacizumab High blood pressure, protein in urine, wound healing problems, rarely bowel perforation Monitoring blood pressure and urine

9. Outlook

Stage Approximate 5-year survival
Stage I About 85-90%
Stage II About 60-70%
Stage III About 20-35%
Stage IV Under 20%

Clear cell carcinoma often does better than serous cancer at stage I, but worse when it has spread, because chemotherapy works less well.

Within stage I, the outlook is best for stage IA and IC1 (tumour confined to the ovary, or rupture during surgery). It is less favourable when the cyst ruptured before surgery, cancer cells are found on the ovarian surface or in abdominal washings (IC2 and IC3).

Survival figures come from women treated years ago and may not reflect newer treatments. Your team can explain what the numbers mean for you.

10. Follow-up

Time after treatment Typical follow-up
Years 1-2 Every 3-4 months: symptoms, examination, CA125 if it was raised, scans if needed
Years 3-5 Every 6 months
After 5 years Yearly or as advised

Women who have had surgery that causes early menopause should discuss bone health and hormone therapy. Hormone replacement is often possible after clear cell carcinoma, but the decision is individual and should be made with the specialist team.

Report new pain, bloating, leg swelling or breathlessness promptly. Gentle exercise, a healthy diet and support from a specialist nurse can help recovery. If Lynch syndrome is found, relatives can be tested, and carriers are offered bowel screening.

11. Research directions

Approach Why it is being studied
Immune checkpoint drugs Some clear cell cancers respond to drugs such as nivolumab or pembrolizumab, sometimes with other drugs
ARID1A-targeted treatments Loss of ARID1A may make cells sensitive to ATR or EZH2 inhibitors
PI3K pathway drugs Target PIK3CA mutations
Anti-angiogenic drugs Block blood vessel growth in the tumour

12. Frequently asked questions

Question Answer
Does endometriosis mean I will get this cancer? No. Fewer than 1 in 100 women with endometriosis develop ovarian cancer
Is it inherited? Usually not, but some cases are linked to Lynch syndrome; genetic testing is offered
Why is my CA125 not very high? Clear cell carcinoma often raises CA125 less than serous cancer does
Will PARP inhibitors help me? They are less useful than in serous cancer, unless a BRCA mutation is present
Why do I need blood thinners? Clear cell carcinoma raises the risk of dangerous blood clots

13. Questions to ask your care team

  • What stage is my cancer, and were the lymph nodes checked?
  • Do I need chemotherapy after surgery?
  • Has my tumour been tested for mismatch repair deficiency, and should I have genetic testing?
  • What is my risk of blood clots, and do I need blood thinners?
  • Are there clinical trials for clear cell carcinoma I could join?
  • Can I take hormone replacement therapy?

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Sugiyama, T. et al. (2000) ‘Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy’, Cancer, 88(11), pp. 2584-2589.
  3. Wiegand, K.C. et al. (2010) ‘ARID1A mutations in endometriosis-associated ovarian carcinomas’, New England Journal of Medicine, 363(16), pp. 1532-1543.
  4. Pearce, C.L. et al. (2012) ‘Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies’, The Lancet Oncology, 13(4), pp. 385-394.
  5. Okamoto, A. et al. (2014) ‘Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary’, International Journal of Gynecological Cancer, 24(9 Suppl 3), pp. S20-S25.
  6. Iida, Y. et al. (2021) ‘Clear cell carcinoma of the ovary: a clinical and molecular perspective’, International Journal of Gynecological Cancer, 31(4), pp. 605-616.
  7. Gonzalez-Martin, A. et al. (2023) ‘Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’, Annals of Oncology, 34(10), pp. 833-848.
  8. National Cancer Institute (2026) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.